CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.
加利福尼亚州南旧金山，2024年11月27日（环球新闻通讯）-- CytomX Therapeutics, Inc.（纳斯达克：CTMX），在被掩蔽的、条件激活的生物制品领域的领先者，今天宣布首席执行官兼董事长Sean McCarthy博士将参加2024年第36届派杰投资医疗会议的炉边聊天，时间为2024年12月4日，上午8:00（东部时间）。
A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at . In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
本次演讲的直播网络广播将在CytomX网站的活动和演讲页面上提供。此外，管理层将与注册参加会议的投资者进行一对一会议。
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX's vision is to create safer, more effective therapies for the treatment of cancer. CytomX's robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates ("ADCs"), T-cell engagers, and immune modulators such as cytokines. CytomX's clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit and follow us on LinkedIn and X (formerly Twitter).
关于cytomx生物制品公司
CytomX是一家临床阶段的以肿瘤为重点的生物制药公司，专注于开发新型条件激活的掩蔽型生物制品，以在肿瘤微环境中局部发挥作用。通过引领以其PROBODY治疗平台为动力的局部生物制品的新型产品线，CytomX的愿景是为癌症治疗创造更安全、更有效的疗法。CytomX的强大而独特的产品线包括抗体-药物结合物（ADCs）.电芯连接剂和细胞因子等免疫调节剂。CytomX的临床阶段产品线包括CX-904，CX-2051和CX-801。CX-904是一个掩蔽的，条件激活的t细胞连接剂，靶向肿瘤细胞上的表皮生长因子受体（EGFR）和t细胞上的CD3受体。CX-904与安进（Amgen）在全球共同开发联盟中合作。CX-2051是一个掩蔽的，条件激活的ADC，定向靶向上皮细胞粘附分子（EpCAM），并携带顶体蛋白酶抑制剂药效成分。CX-2051在多个表达EpCAM的上皮癌症中具有潜在适用性，并与AbbVie旗下的Immunogen合作发现。CX-801是一个掩蔽的干扰素α-2亿次PROBODY细胞因子，对传统的免疫治疗敏感肿瘤以及不敏感（冷）肿瘤具有广泛潜力适用性。CytomX已与肿瘤领域的多个领军企业建立了战略合作关系，包括安进（Amgen），阿斯利康（Astellas），百时美施贵宝（Bristol Myers Squibb），再生元（Regeneron）和Moderna。有关CytomX以及它如何努力将条件激活治疗作为针对癌症的新标准，更多信息请访问该网站，并关注我们的LinkedIn和X（前身为Twitter）页面。
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
公司联系人：
克里斯•奥格登
高级副总裁，首席财务官
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
投资者联系人：
Precision AQ（前斯特恩投资者关系）
斯蒂芬妮•阿舍
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
媒体联系：
Redhouse Communications
特里•达尔曼
teri@redhousecomms.com
译文内容由第三方软件翻译。
